News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better Shelley Wood March 10, 2023
News Conference News ACC 2023 MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis Michael O'Riordan March 10, 2023
News Conference News ACC 2023 ‘Causal AI’ May Help Guide Specific Actions to Reduce CVD Risk Caitlin E. Cox March 10, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2023 No Downside to Immediate Complete Revascularization in ACS: BIOVASC Michael O'Riordan March 06, 2023
Presentation ACC 2023 Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III) Presenter: Annapoorna S. Kini March 06, 2023
News Conference News ACC 2023 For Complex PCI, Intravascular Imaging Lowers Risk of TVF Michael O'Riordan March 05, 2023
News Conference News ACC 2023 On-site Machine Learning-Based FFRCT Feasible, Informative: TARGET Caitlin E. Cox March 04, 2023
News Conference News ACC 2023 Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III Shelley Wood March 04, 2023